Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

SHR-9839

Phase 2Small molecule

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

SHR-9839 is one of 127 small molecule programs targeting NSCLC. It is currently in Phase 2.

4

Indications

5

Total Trials

5

Active Trials

126

Competitors

Pipeline

Status by Indication[3][1]

Indication

NSCLCRecruiting

Solid TumorsRecruiting

Patients With Advanced Solid TumorsActive, not recruiting

Recurrent/metastatic Head and Neck Squamous Cell CarcinomaRecruiting

NSCLCPhase 2

Recruiting

Solid TumorsPhase 2

Recruiting

Patients With Advanced Solid TumorsPhase 2

Active, not recruiting

Recurrent/metastatic Head and Neck Squamous Cell CarcinomaPreclinical

Recruiting

Competition

Competitive Landscape

225 competitors in Patients With Advanced Solid Tumors

#DrugCompanyPhaseTrials

Avastin

Lynparza

Beyfortus

Halaven

Adriamycin

Cyramza

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Vepesid

Ensacove

XXcovery Holdings, Inc.

Albumin-Bound Paclitaxel

Bristol-Myers Squibb

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1/2Recruiting

Solid Tumors

NCT06703177

Q4 2027

Phase 1/2Recruiting

NSCLC

NCT06754930

Q1 2029

PreclinicalRecruiting

Recurrent/metastatic Head and Neck Squamous Cell Carcinoma

NCT07059221

Clinical

Trials by Indication[1]

Patients With Advanced Solid Tumors2 trials

A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Active, not recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 1/2·NCT06385678·47 enrolled

The Clinical Study of SHR-9839 for Injection in Patients With Advanced Solid Tumors

Recruiting· Shanghai Hengrui Pharmaceutical Co., Ltd. logo

Shanghai Hengrui Pharmaceutical Co., Ltd.·Phase 1·NCT05836948·174 enrolled

NSCLC1 trial

A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC

Recruiting· Suzhou Suncadia Biopharmaceuticals Co., Ltd. logo

Suzhou Suncadia Biopharmaceuticals Co., Ltd.·Phase 1/2·NCT06754930·400 enrolled

Solid Tumors1 trial

A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors

Recruiting· Suzhou Suncadia Biopharmaceuticals Co., Ltd. logo

Suzhou Suncadia Biopharmaceuticals Co., Ltd.·Phase 1/2·NCT06703177·876 enrolled

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma1 trial

A Multicenter, Open-label Phase Ib/II Clinical Trial of SHR-A2102 Injection in Combination With Adebrelimab Injection, With or Without Other Anti-tumor Therapies, in Subjects With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Recruiting· Suzhou Suncadia Biopharmaceuticals Co., Ltd. logo

Suzhou Suncadia Biopharmaceuticals Co., Ltd.·Preclinical·NCT07059221·210 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for SHR-9839. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SHR-9839 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SHR-9839. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Suzhou Suncadia Biopharmaceuticals Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Related News